Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

RBOT FINANCIAL STATEMENTS

Vicarious Surgical Inc. — balance sheet, income statement and cash flow trends

RBOTVicarious Surgical Inc.

🇺🇸 USA · NYSE · Healthcare · Medical Devices

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
-50 M0202120222023202420252026

Profit Funnel

Q1 2026 · TTM
Revenue0 $Gross Profit-1.2 M $ · -Infinity%Operating Income-42.7 M $ · -Infinity%Pre-tax Income-42.1 M $ · -Infinity%Net Income-42.1 M $ · -Infinity%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue0 $-100.0%
Gross Profit-1.2 M $—
Operating Income-42.7 M $—
EBITDA-40.9 M $—
Net Income-42.1 M $—

Peer Comparison· Medical Devices

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
RBOT-100.0%———
ANGEN11.7%58.8%9.8%-45.0%
Industry median7.4%58.9%5.2%-5.7%
CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
RBOT-100.0%———
RCEL1.0%81.4%-52.1%-62.7%
XAIR107.3%3.3%-330.7%-433.0%
Industry median7.4%58.9%5.2%-5.7%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0100 M200 M300 M202120222023202420252026

Capital Structure

Q1 2026
Total Assets12.6 M
  • Equity3.6 M $28%
  • Current Liabilities3.3 M $27%
  • Long-term Liabilities5.7 M $45%

Key Figures

YoY change
Total Assets12.6 M $-77.1%
Total Liabilities9 M $-57.0%
Total Equity3.6 M $-89.5%
Cash & ST Investments3.7 M $-90.1%
Total Debt7.2 M $-46.7%
Net Debt5.8 M $-46.9%

Peer Comparison· Medical Devices

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
RBOT1.54201.5%-0.0928.4%
ANGEN2.3128.1%4.7167.2%
Industry median3.2844.7%0.8249.7%
CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
RBOT1.54201.5%-0.0928.4%
RCEL0.47-207.7%-0.90-44.9%
XAIR3.80381.7%-0.4617.3%
Industry median3.2844.7%0.8249.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-50 M-25 M0202120222023202420252026

Cash Flow Bridge

Q1 2026 · TTM
-40 M-20 M0-39.5 M $Operating32.5 M $Investing5.6 M $Financing-1.4 M $Net Change

Key Figures

YoY change
Operating Cash Flow-39.5 M $—
Capital Expenditures135.7 K $-34.4%
Free Cash Flow-39.7 M $—
Dividends Paid——

Peer Comparison· Medical Devices

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
RBOT———93.9%
ANGEN40.2%-21.2%61.5%-89.3%
Industry median7.2%1.5%4.1%76.6%
CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
RBOT———93.9%
RCEL-42.8%-42.5%4.4%68.3%
XAIR-236.3%-249.6%13.3%54.6%
Industry median7.2%1.5%4.1%76.6%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on RBOT

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.